Reshape Stock Analysis

The latest indifference towards the small price fluctuations of Reshape Lifesciences created some momentum for retail investors as it was traded today as low as 0.0 and as high as 0.0 per share. The company executives did not add any value to Reshape Lifesciences investors in June. However, most investors can still diversify their portfolios with Reshape Lifesciences to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to retail investors with longer-term investment horizons.
Check out Your Equity Center.

Search Stock Analysis 

 
Refresh
The Reshape Lifesciences stock analysis report makes it easy to digest most publicly released information about Reshape Lifesciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Reshape Stock analysis module also helps to analyze the Reshape Lifesciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Reshape Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.79. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Reshape Lifesciences recorded a loss per share of 3.19. The entity had not issued any dividends in recent years. The firm had 1-120 split on the 12th of November 2019. ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences is traded on NASDAQ Exchange in the United States. To find out more about Reshape Lifesciences contact Barton Bandy at 949 429 6680 or learn more at http://www.reshapelifesciences.com.

Reshape Lifesciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Reshape Lifesciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Reshape Lifesciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Reshape Lifesciences is not yet fully synchronised with the market data
Reshape Lifesciences has some characteristics of a very speculative penny stock
Reshape Lifesciences has high likelihood to experience some financial distress in the next 2 years
The company currently holds 13.67 M in liabilities with Debt to Equity (D/E) ratio of 1.08, which is about average as compared to similar companies. Reshape Lifesciences has a current ratio of 0.37, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
The entity reported the previous year's revenue of 11.73 M. Net Loss for the year was (22.19 M) with profit before overhead, payroll, taxes, and interest of 6.26 M.
Reshape Lifesciences currently holds about 896 K in cash with (7.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14.
Over 97.0% of Reshape Lifesciences shares are owned by institutional investors

Reshape Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 22.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Reshape Lifesciences's market, we take the total number of its shares issued and multiply it by Reshape Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Reshape Profitablity

Reshape Lifesciences' profitability indicators refer to fundamental financial ratios that showcase Reshape Lifesciences' ability to generate income relative to its revenue or operating costs. If, let's say, Reshape Lifesciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Reshape Lifesciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Reshape Lifesciences' profitability requires more research than a typical breakdown of Reshape Lifesciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (189.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (93.2) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.93.

Management Efficiency

The entity has return on total asset (ROA) of (18.58) % which means that it has lost $18.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (129.5) %, meaning that it created substantial loss on money invested by shareholders. Reshape Lifesciences management efficiency ratios could be used to measure how well reshape lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.

Reshape Lifesciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reshape Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reshape Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reshape Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Armistice Capital Llc over a month ago via Macroaxis 
Exercise of in-the-money or at-the-money derivative position by Armistice Capital Llc of tradable shares of Reshape Lifesciences
Armistice Capital Llc over a month ago via Macroaxis 
Exercise of in-the-money or at-the-money derivative position by Armistice Capital Llc of tradable shares of Reshape Lifesciences
Stankovich Thomas over a month ago via Macroaxis 
Reshape Lifesciences exotic insider transaction detected
Armistice Capital Llc over a month ago via Macroaxis 
Sale by Armistice Capital Llc of tradable shares of Reshape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
Purchase by Armistice Capital Llc of tradable shares of ReShape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
Purchase by Armistice Capital Llc of tradable shares of ReShape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
Purchase by Armistice Capital Llc of tradable shares of ReShape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
Purchase by Armistice Capital Llc of tradable shares of ReShape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
Purchase by Armistice Capital Llc of tradable shares of ReShape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
Purchase by Armistice Capital Llc of tradable shares of ReShape Lifesciences
Stankovich Thomas over six months ago via Macroaxis 
Purchase by Stankovich Thomas of 530 shares of ReShape Lifesciences
Armistice Capital Llc over six months ago via Macroaxis 
ReShape Lifesciences exotic insider transaction detected

Reshape Lifesciences Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Reshape Lifesciences to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module
Check out Your Equity Center. Note that the Reshape Lifesciences information on this page should be used as a complementary analysis to other Reshape Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Other Tools for Reshape Stock

When running Reshape Lifesciences price analysis, check to measure Reshape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reshape Lifesciences is operating at the current time. Most of Reshape Lifesciences' value examination focuses on studying past and present price action to predict the probability of Reshape Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Reshape Lifesciences' price. Additionally, you may evaluate how the addition of Reshape Lifesciences to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go